One in 10 persons in the world aged 40 years and older will develop the syndrome of
HFpEF (heart failure with preserved ejection fraction), the most common form of chronic …

Heart failure (HF) is a complex clinical syndrome characterized by the activation of at least
several neurohumoral pathways that have a common role in maintaining cardiac output and …

Heart failure (HF) is a complex syndrome that affects approximately 6.5 million adults in the
United States. About half of the 6.5 million adults with HF are estimated to be individuals with …

In contrast to the wealth of proven therapies for heart failure with reduced ejection fraction
(HFrEF), therapeutic efforts in the past have failed to improve outcomes in heart failure with …

Heart failure with preserved ejection fraction (HFpEF) is an increasingly studied entity
accounting for 50% of all diagnosed heart failure and that has claimed its own dignity being …

Cardiac fibrosis is a common pathological consequence of most myocardial diseases. It is
associated with the excessive accumulation of extracellular matrix proteins as well as …

Over the last several decades, clinicians and clinical scientists have had growing interest in
heart failure (HF) diagnosis and treatment. While HF with reduced ejection fraction (EF) is a …

Myocardial fibrosis is an endogenous response to different cardiac insults that may become
maladaptive over time and contribute to the onset and progression of heart failure (HF) …

Cardiovascular diseases are one of the leading causes of death worldwide and cardiac
fibrosis is a common pathological process for cardiac remodeling in cardiovascular …

Heart failure (HF) with preserved ejection fraction (HFpEF) is a leading cause of
hospitalizations and mortality when diagnosed at the age of≥ 65 years. HFpEF represents …